Bioequivalence of Canagliflozin 300 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.
This study is looking at a new version of a diabetes drug called Canagliflozin, specifically a 300 mg tablet. Its main goal is to check if this new tablet is "bioequivalent" to the original one. This means ensuring that the body absorbs and uses the medicine in the exact same way. They are testing this in healthy volunteers who haven't eaten before taking the drug, to get a clear picture of how it works without food affecting it. This kind of research, called a bioequivalence study, is important because it helps ensure that different versions of a medicine are just as effective and safe as each other, before they can be made widely available to patients. It’s an essential step in developing new medicines.
At a glance
What is this study about?
Imagine you have a favourite biscuit, and a new company makes their own version. This study is a bit like that, but for medicine. The medicine in question is called Canagliflozin, and it's used by people with diabetes. This study is testing a new tablet form of this medicine.
The main aim is to see if this new 300 mg tablet works just as well as the original version. This is called a 'bioequivalence' study. It means they want to make sure your body absorbs the medicine in the new tablet and uses it in the same way and at the same speed as the original one. It’s like ensuring the new biscuit has the exact same amount of sugar and flavouring as your favourite brand.
They are doing this study with healthy people, not people with diabetes. This is so they can clearly see how the medicine behaves in the body without other health conditions affecting the results. Participants will take the medicine after a period of not eating, which helps scientists get the clearest possible information about how the drug is absorbed without food interfering. This research is a really important step to make sure that any new version of a medicine is safe, reliable, and just as effective as the original, before it can be given to patients.
Key takeaways
- This study tests a new version of a diabetes medicine called Canagliflozin.
- It aims to confirm the new tablet works exactly like the original one (bioequivalence).
- Healthy adult volunteers, aged 18 and over, are needed.
- Participants will take the medicine after fasting and be closely monitored.
- The research helps ensure new medications are safe and effective for patients.
Who may be eligible?
This study is looking for healthy adult volunteers. You need to be at least 18 years old to take part, and there's no upper age limit mentioned.
Because this study focuses on how the body handles the medicine in healthy people, you won't be able to join if you have certain medical conditions or are taking specific medications that might affect the results. They'll check your health carefully to make sure you're a good fit.
Both men and women are welcome to take part in this study. The medical team will explain all the specific health requirements during a screening visit to see if you're eligible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you consider yourself generally healthy?
- Are you able to follow study instructions carefully?
- Are you willing to fast (not eat) for a specified period for the study?
- Do you not have any major ongoing health conditions?
What does participation involve?
If you decide to take part, you'll first have a screening visit. This involves a health check, including a review of your medical history, a physical exam, and blood and urine tests, to make sure you're healthy enough for the study. If you qualify, you'll be given the study medicine, Canagliflozin, usually a single dose, after a period of not eating (fasting).
You'll stay at the study clinic for a set amount of time, typically a short stay, where doctors and nurses will monitor you closely. They will take blood samples regularly to measure how much of the medicine is in your body over time. This helps them understand how the medication is absorbed and processed. There might also be follow-up visits or calls after you leave the clinic to check on your well-being. The total duration of your participation, including screening, the study visit, and any follow-up, will be explained in detail before you agree to join.
Potential risks and benefits
Locations (1)
- —UnverifiedPortugal
Common questions
What is Canagliflozin normally used for?
Canagliflozin is a medicine usually prescribed to help people with type 2 diabetes manage their blood sugar levels.
Why are they testing this in healthy people?
They test in healthy people to clearly see how the body absorbs and processes the medicine without other health conditions affecting the results.
What does 'bioequivalence' mean?
It means they're checking if the new tablet works in the exact same way as the original one, making sure your body absorbs and uses the medicine similarly.
Will I get paid for taking part?
Many studies offer compensation for your time and travel, but you should ask the study team for specific details.
Can I stop participating if I change my mind?
Yes, you can withdraw from the study at any time without needing to give a reason, and it won't affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.